Nature | Medicine
Follow
Eplontersen with and without background transthyretin stabilizers in transthyretin amyloid cardiomyopathy: secondary analysis of a phase 3, randomized controlled trial
As presented at the 2026 ESC Congress, in a secondary analysis of the CARDIOTTRansform trial testing the transthyretin-targeting antisense oligonucleotide eplontersen in patients with transthyretin amyloid cardiomyopathy, a beneficial effect was observed in patients who were not on transthyretin stabilizers at baseline, but not in those who were on stabilizers.
